1Balat O. Paclitaxel/carboplatin versus cyclophosphamide/carboplatin in peritoneal carcinomatosis of the ovary[J]. Eur J Gynaecol Oncol, 2004, 25 (2): 195～196
2Shibata K, Kikkawa F, Suzuki Y, et al. Neoadjuvant chemotherapy for FIGO stage Ⅲ or Ⅳ ovarian cancer: survival benefit and prognostic factors[J]. Int J Gynecol Cancer, 2003, 13(3):587～592
3Chi DS, Liao JB, Leon LF, et al. Identification of prognostic factors in advanced epithelial ovarian carcinoma [J]. Gynecol Oncol,2001, 82(2): 532～537
4Bristow RE, Tomacruz RS, Armstrong DK, et al. Survival effect of maximal cytoreductive surgery foradvanced ovarian carcinoma during the platinum era: a meta-analysis [J]. J Clin Oncol, 2002,20(5): 1248～1259
5Kuhn W, Rutke S, Spathe K, et al. Neoadjvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in Intenational Federation of Gynecology and Obstetrics stage Ⅲ c ovarian carcinoma [J]. Cancer, 2001, 92 (10):2585 ～2591
6Jacob JH, Gershenson DM, Morris M, et al. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer[J]. Gynecol Oncol, 1991, 42(2): 146～150
7Vergote I, De Wever I, Tjalma W, et al. Neoadjvant chemotherapy or primary debulking surgery in advanced ovarian carcinoma:a retrospective analysis of 285 patients [J]. Gynecol Oncol, 1998,71(3): 431～436
8Ansquer Y, Leblanc E, Clough K, et al. Neoadjvant chemotherapy for unresectable ovarian carcinoma: a French multicenter study [J]. Cancer, 2001, 91(12): 2329～2334
9Schwartz PE, Rutherford TJ, Chambers JT, et al. Neoadjvant chemotherapy for advanced ovarian cancer: long-term survival[J].Gynecol Oncol, 1999, 729(1): 93～99
10Nelson BE, Rosenfield AT, Schwartz PE. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma [J].J Clin Oncol, 1993, 11(1): 166～172
